A Bile Acid Medication Showed Promise in Animals—but Fell Short in Humans with Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a serious complication of Type 1 diabetes, where high blood sugar gradually damages the kidneys' filtering units. One early sign is albuminuria—excess protein leaking into the urine—which indicates kidney function is declining.

Researchers have long used animal models to explore potential treatments before testing them in humans. In laboratory studies, ursodeoxycholic acid (UDCA), a bile acid already used clinically for other conditions, showed promise: it reduced protein in the urine and improved kidney tissue damage in diabetic animals.

These promising animal results led scientists to ask: would UDCA work the same way in people with Type 1 diabetes and established kidney disease?

Researchers in this single-center trial recruited 31 people with Type 1 diabetes and diabetic kidney disease who still had albuminuria—protein in their urine—even while on maximum tolerated doses of kidney-protective medications (renin-angiotensin system blockers). All participants had kidney function measured as eGFR ≥ 30 ml/min, meaning they retained reasonable kidney capacity at baseline.

The study used a crossover design: participants randomly received either UDCA (500 mg twice daily) or placebo for 24 weeks, then had a 4-week break, then received the other treatment. This approach allows researchers to compare each person's response to both active drug and placebo.

The primary goal was to measure whether UDCA reduced the amount of albumin in the urine—a key marker of kidney health—compared to placebo.

Twenty-one of the 31 participants were men, with a median age of 54.2 years. At the start, participants on the UDCA arm had a median urine albumin excretion rate of 26 μg/min, while those on placebo had 32.1 μg/min.

After 24 weeks of UDCA treatment, the median excretion rate rose to 36.2 μg/min. On placebo, it rose to 38.5 μg/min. This difference was not statistically significant (p = 0.4), meaning the researchers could not conclude that UDCA reduced albuminuria more than placebo did.

This was the first study of its kind testing UDCA in humans with Type 1 diabetes and kidney disease. The fact that it did not show a benefit does not prove the drug cannot help, but it does suggest the effect—if it exists—is not large enough to detect with this study size and duration.

It's possible that different doses, longer treatment periods, or different patient populations might yield different results. Animal models sometimes point to promising directions that don't translate directly to humans, and the reverse can also be true.

This research highlights an important principle: promising laboratory findings are a starting point, not a guarantee. Rigorous clinical testing in humans remains essential before any new approach can be recommended for patient care.

Source: Frontiers in endocrinology. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.